You are here

  • Home
  • Archive
  • Volume 81, Issue 8
  • Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

Citation Tools

Article menu
Rheumatoid arthritis
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Daien C, Krogulec M, Gineste P, et al
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study
Annals of the Rheumatic Diseases 2022;81:1076-1084.